Research Summary

I am an academic neuro-oncologist, focused on caring for adult patients with primary brain tumors. In addition to my neurology and neuro-oncology training, I also have a Masters in Public Health (MPH), which I apply to clinical trial development and analysis. I am very active in research areas of novel treatment strategies to improve outcomes for patients with gliomas. I collaborate and serve as the principle investigator on several investigator-initiated, industry-sponsored, and consortia trials. I am involved in the UCSF federal SPORE grant investigating novel ways of investigating the relationship of the immune system with glioma. I also lead our research efforts investigating strategies for improving cognition, quality-of-life, and palliative care for our patients, as well as their caregivers. 


  • Randolph-Macon Woman's College, B.S., 06/2001, Biology 
  • University of Kentucky College of Medicine, 06/2007, M.D. 
  • University of Virginia, Residency, 06/2011, Neurology 
  • Massachusetts General Hospital/Dana Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Fellowship, 06/2014, Neuro-Oncology 
  • Harvard School of Public Health, 06/2014, MPH 

Honors & Awards

  • 2007
    General Clinical Research Center Medical/Dental Mentorship Award, University of Kentucky College of Medicine
  • 2010
    Chief resident in Neurology, University of Virginia College of Medicine
  • 2012
    K12 training grant recipient, "Training Program in Nervous System Tumors", Massachusetts General Hospital

Selected Publications

  1. Taylor JW. Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma? Neuro Oncol. 2021 Nov 27.  View on PubMed
  2. Molinaro AM, Wiencke JK, Warrier G, Koestler DC, Chunduru P, Lee JY, Hansen HM, Lee S, Anguiano J, Rice T, Bracci PM, McCoy L, Salas LA, Christensen BC, Wrensch M, Kelsey KT, Taylor JW, Clarke JL. Interactions of Age and Blood Immune Factors and Non-Invasive Prediction of Glioma Survival. J Natl Cancer Inst. 2021 Oct 01.  View on PubMed
  3. Lucas CG, Mueller S, Reddy A, Taylor JW, Oberheim Bush NA, Clarke JL, Chang SM, Gupta N, Berger MS, Perry A, Phillips JJ, Solomon DA. Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro Oncol. 2021 Sep 14.  View on PubMed
  4. Weyer-Jamora C, Brie MS, Luks TL, Smith EM, Hervey-Jumper SL, Taylor JW. Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients. Neurosurgery. 2021 Feb 15.  View on PubMed
  5. Weyer-Jamora C, Brie MS, Luks TL, Smith EM, Braunstein SE, Villanueva-Meyer JE, Bracci PM, Chang S, Hervey-Jumper SL, Taylor JW. Cognitive impact of lower-grade gliomas and strategies for rehabilitation. Neurooncol Pract. 2021 Apr; 8(2):117-128.  View on PubMed
  6. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa142.  View on PubMed
  7. Lukas RV, Taylor JW, Kurz SC, Mohile NA. Clinical neuro-oncology for the neurologist. Neurol Clin Pract. 2020 Oct; 10(5):458-465.  View on PubMed
  8. Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, Cooney T, Cham E, Jin LW, Khatib Z, Maher O, Chamyan G, Brathwaite C, Bannykh S, Mueller S, Kline CN, Banerjee A, Reddy A, Taylor JW, Clarke JL, Oberheim Bush NA, Butowski N, Gupta N, Auguste KI, Sun PP, Roland JL, Raffel C, Aghi MK, Theodosopoulos P, Chang E, Hervey-Jumper S, Phillips JJ, Pekmezci M, Bollen AW, Tihan T, Chang S, Berger MS, Perry A, Solomon DA. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathol Commun. 2020 08 28; 8(1):151.  View on PubMed
  9. Schulte JD, Aghi MK, Taylor JW. Anti-angiogenic therapies in the management of glioblastoma. Chin Clin Oncol. 2021 Aug; 10(4):37.  View on PubMed
  10. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019 07; 15(7):405-417.  View on PubMed
  11. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol Pract. 2019 Sep; 6(5):364-374.  View on PubMed
  12. Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, Schrag D, Wen PY. The lomustine crisis: awareness and impact of the 1500% price hike. Neuro Oncol. 2019 01 01; 21(1):1-3.  View on PubMed
  13. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 2018 Nov; 140(2):477-483.  View on PubMed
  14. Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639.  View on PubMed
  15. Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017 06; 133(6):1001-1016.  View on PubMed
  16. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610.  View on PubMed
  17. Taylor JW, Molinaro AM, Butowski N, Prados M. Clinical trial endpoints for patients with gliomas. Neurooncol Pract. 2017 Dec; 4(4):201-208.  View on PubMed
  18. Cabrera JR, Taylor JW, Molinaro AM. Phase I cancer clinical trials. Neurooncol Pract. 2017 Mar; 4(1):67-72.  View on PubMed
  19. Chan AK, Birk HS, Winkler EA, Viner JA, Taylor JW, McDermott MW. Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report. Cureus. 2016 Jul 07; 8(7):e675.  View on PubMed
  20. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.  View on PubMed

Go to UCSF Profiles, powered by CTSI